Daisuke Ito
Broad Institute
4 Papers
12 Citations
Daisuke Ito is an academic researcher from Broad Institute. The author has contributed to research in topics: Isocitrate dehydrogenase & Prodrug. The author has an hindex of 4, co-authored 4 publications. Previous affiliations of Daisuke Ito include Harvard University.
Chat about Author
Papers
An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules
Amrita Basu,Nicole E. Bodycombe,Jaime H. Cheah,Edmund Price,Ke Liu,Giannina Ines Schaefer,Richard Y. Ebright,Michelle Stewart,Daisuke Ito,Stephanie Wang,Abigail L. Bracha,Ted Liefeld,Mathias Wawer,Joshua C. Gilbert,Andrew J. Wilson,Nicolas Stransky,Gregory V. Kryukov,Vlado Dančík,Jordi Barretina,Levi A. Garraway,C. Suk-Yee Hon,Benito Munoz,Joshua A. Bittker,Brent R. Stockwell,Dineo Khabele,Andrew M. Stern,Paul A. Clemons,Alykhan F. Shamji,Stuart L. Schreiber +28 more
TL;DR: A candidate dependency is reported, associating activating mutations in the oncogene β-catenin with sensitivity to the Bcl-2 family antagonist, navitoclax, which can be used to develop novel therapeutic hypotheses and to accelerate discovery of drugs matched to patients by their cancer genotype and lineage.
771
Patent
Compounds and methods for the treatment of isocitrate dehydrogenase related diseases
Mahmud M. Hussain,Daisuke Ito,Jason M. Law,Matthias Leiendecker,Ke Liu,Benito Munoz,Stuart L. Schreiber,Alykhan F. Shamji,Andrew M. Stern +8 more
- 26 Sep 2013
TL;DR: In this paper, the invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof, which are defined as compounds of formula I.
12
Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1
Jason M. Law,Sebastian C. Stark,Ke Liu,Norah E. Liang,Mahmud M. Hussain,Matthias Leiendecker,Daisuke Ito,Oscar Verho,Andrew M. Stern,Stephen Johnston,Yan-Ling Zhang,Gavin P. Dunn,Alykhan F. Shamji,Stuart L. Schreiber +13 more
TL;DR: A potent (IC50 = 50 nM) series of IDH1-R132H inhibitors having 8-membered ring sulfonamides as exemplified by the compound BRD2879 is reported, which suppress (R)-2-hydroxyglutarate production in cells without apparent toxicity.
NAMPT is the cellular target of STF-31-like small-molecule probes.
Drew J. Adams,Daisuke Ito,Matthew G. Rees,Brinton Seashore-Ludlow,Xiaoling Puyang,Alex H. Ramos,Jaime H. Cheah,Paul A. Clemons,Markus Warmuth,Ping Zhu,Alykhan F. Shamji,Stuart L. Schreiber +11 more
TL;DR: Cancer-cell profiling and genomic approaches identify NAMPT inhibition as a critical mechanism by which STF-31-like compounds inhibit cancer cells.